PF 04937319,葡糖激酶部分激活剂

更新时间:2024-01-12 12:45:51

PF 04937319,葡糖激酶部分激活剂结构式
PF 04937319,葡糖激酶部分激活剂结构式
品牌特惠专场
常用名 PF 04937319,葡糖激酶部分激活剂 英文名 PF 04937319
CAS号 1245603-92-2 分子量 432.432
密度 1.4±0.1 g/cm3 沸点 N/A
分子式 C22H20N6O4 熔点 N/A
MSDS 美版 闪点 N/A

 PF 04937319,葡糖激酶部分激活剂用途


PF-04937319 是一种葡萄糖激酶活化剂 (GKA),EC50 值为 154.4 μM,有望用来治疗 2 型糖尿病。PF-04937319 旨在维持降糖功效,同时降低许多其他 GKA 观察到的低血糖风险。

 PF 04937319,葡糖激酶部分激活剂名称

中文名 PF 04937319,葡糖激酶部分激活剂
英文名 7E99B9ZM19
英文别名 更多

 PF 04937319,葡糖激酶部分激活剂生物活性

描述 PF-04937319 是一种葡萄糖激酶活化剂 (GKA),EC50 值为 154.4 μM,有望用来治疗 2 型糖尿病。PF-04937319 旨在维持降糖功效,同时降低许多其他 GKA 观察到的低血糖风险。
相关类别
靶点

EC50: 154.4 μM (GSA) (PF-04937319)[1]

参考文献

[1]. Dzyurkevich MS, et al. Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus. Sci Rep. 2017 Nov 22;7(1):16072.

[2]. Amin NB, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9.

 PF 04937319,葡糖激酶部分激活剂物理化学性质

密度 1.4±0.1 g/cm3
分子式 C22H20N6O4
分子量 432.432
精确质量 432.154602
LogP 1.29
外观性状 粉末
折射率 1.667
储存条件 2-8°C, 密封, 干燥

 PF 04937319,葡糖激酶部分激活剂安全信息

危险品运输编码 NONH for all modes of transport

 PF 04937319,葡糖激酶部分激活剂文献3

更多文献
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.

Diabetes Obes. Metab. 17(8) , 751-9, (2015)

To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF-04937319, as add-on therapy to metformin, in patients with type 2 diabetes mellitus (T2DM).Patie...

Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator.

Drug Metab. Dispos. 42(11) , 1926-39, (2014)

The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-ca...

The relationship of glucokinase activator-induced hypoglycemia with arteriopathy, neuronal necrosis, and peripheral neuropathy in nonclinical studies.

Toxicol. Pathol. 42(4) , 696-708, (2014)

Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF-04651887, piragliatin, and PF-04937319) was assessed in mice, rats, dogs...

 PF 04937319,葡糖激酶部分激活剂英文别名

2-Pyrimidinecarboxamide, N,N-dimethyl-5-[[2-methyl-6-[[(5-methyl-2-pyrazinyl)amino]carbonyl]-4-benzofuranyl]oxy]-
N,N-Dimethyl-5-({2-Methyl-6-[(5-Methylpyrazin-2-Yl)carbamoyl]-1-Benzofuran-4-Yl}oxy)pyrimidine-2-Carboxamide
7E99B9ZM19
N,N-Dimethyl-5-({2-methyl-6-[(5-methyl-2-pyrazinyl)carbamoyl]-1-benzofuran-4-yl}oxy)-2-pyrimidinecarboxamide
PF-04937319
品牌现货直购
推荐供应商:


查看所有供应商和价格请点击:

PF 04937319,葡糖激酶部分激活剂生产厂家

PF 04937319,葡糖激酶部分激活剂价格